SIS-202-CDC

N/A

Report date: 2024/09/29 16:11:13

Base Information

Drug NameSIS-202-CDC
Drug Alias NameSIS-202-CDC
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionTransforming growth factor beta 1 modulators
TargetsTransforming growth factor beta 1
Therapy Area/IndicationsCorneal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvellino Labs Usa IncSiSaf Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAvellino Labs Usa IncSiSaf Ltd
Inactive CompaniesN/A
Active IndicationsCorneal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A